People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ascus Biosciences, Inc. | — | Biotech / Pharma | Series A | $28.7M | $167.5M | 2016 |
| Ecto, Inc. | — | Other Technology | Series A | $16.9M | $613K | 2021 |
Thad Simons at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thad Simons on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jim Kim | 1 | 4 |
| David Matias | 1 | 3 |
| Erik Torgerson | 1 | 3 |
| Kieran Furlong | 1 | 2 |
| James Webb | 1 | 2 |
| David B. Matias | 1 | 2 |
| Peter Innes | 1 | 1 |
| Mallory Embree | 1 | 1 |
| Alex Stimpson | 1 | 1 |
| Vladimir Cernavskis | 1 | 1 |
| Kim Wagenaar | 1 | 1 |
| Vladimir B. Cernavskis | 1 | 1 |
| Thad B. Simons | 1 | 1 |
| Dmitry Kozachenok | 1 | 1 |
| Mike Velings | 1 | 1 |
| Mike B. Velings | 1 | 1 |
| Michael Seely | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.